Skip to main content

Table 1 The demographic characteristics, underlying diseases, and mortality rates among non-HIV patients with PJP according to pulmonary CMV infection status

From: Outcomes and prognostic factors of non-HIV patients with pneumocystis jirovecii pneumonia and pulmonary CMV co-infection: A Retrospective Cohort Study

  CMV-DNA positive in BALF (n = 38) CMV-DNA negative in BALF(n = 32) p
Demographics
 Age, yr., median 51(21–77) 48(22–81) 0.48
 Gender ratio(male:female) 23:15 20:12 0.87
Underlying diseases,n(%)
 Solid organ transplantation 3(7.9) 3(9.4) 1.00
 Hematologic malignancy 4(10.5) 9(28.2) 0.06
 Hematopoietic stem cell transplantation 3(75) 4(44.4)  
  Non-hematologic malignancy 2(5.3) 2(6.3) 1.00
 Dermatologic diseases 4(10.5) 5(15.6) 0.78
  Kidney disease 12(31.5) 5(15.6) 0.12
  Interstitial lung disease 0(0) 1(3.1) 1.00
  Connective tissue disease 9(23.7) 5(15.6) 0.40
 Idiopathic thrombocytopenia 2(5.3) 1(3.1) 1.00
  Others 2(5.3) 1(3.1) 1.00
Immunosuppressive agents,n(%)
 Steroids 37(97.4) 31(96.9) 1.00
 Dosage of steroid, recent 1 month(mg) 40(10–100) 45(10–300) 0.54
 Steroid + T-cell immunosuppressants 28(73.7) 15(65.2) 0.02
  Steroid +Anti-CD20+ monoclonal antibodya 1(2.6) 6(18.8) 0.06
 Chemotherapy/Radiotherapy 2(5.3) 3(9.4) 0.84
Treatment for PJP
 TMP-SMZ(%) 33(86.8) 31(96.9) 0.29
 Treatment duration, days, median 15(4–31) 21(2–23) 0.051
 Shift to second-line therapyb(%) 23(60.5) 12(37.5) 0.055
  Due to treatment failure 18(47.4) 11(34.4) 0.27
  Due to adverse reactionc 5(13.2) 1(3.1) 0.29
Morbidity,n(%)
 Admitted to ICU 16(42.1) 9(28.2) 0.22
 Mechanical ventilation 14(36.8) 8(25.0) 0.29
 Mortality 17(44.7) 9(28.2) 0.15
  1. aRituximab
  2. bsecond-line therapy: primaquine plus clindamycin and caspofungin
  3. cAdverse reactions included thrombocytopenia, bone marrow suppression, and drug allergy (2 cases)
  4. PJP Pneumocystis jirovecii pneumonia, CMV cytomegalovirus, BALF bronchoalveolar lavage fluid, TMP-SMZ sulfamethoxazole and trimethoprim, ICU intensive care unit